Effects of Butylphthalide on Relevant Molecular Markers and ABCD2 Score in Patients with Non-Disabling Ischemic Cerebrovascular Disease
OBJECTIVE:To probe into the effects of combined application of butylphthalide on ABCD2 score and related molecular markers in patients with non-disabling ischemic cerebrovascular disease,and to evaluate its clinical therapeutic effect.METHODS:A total of 100 patients with non-disabling ischemic cerebrovascular disease hospitalized in the hospital from Feb.2021 to Feb.2023 were selected to be divided into the observation group(n=50)and control group(n=50)by random sampling method through random number table tool.The control group was given conventional cerebrovascular disease treatment regimen,while the observation group received butylphthalide on the basis of the control group,all patients were treated continuously for 1 month.Changes of ABCD2 scores,National Institutes of Health Stroke Neurological Impairment Scale(NIHSS)scores and Activity of Daily Living(ADL)scores,C-reactive protein(CRP),homocysteine(Hcy),S100A1 protein,interleukin 6(IL-6)and superoxide dismutase(SOD)levels were compared between two groups before and after treatment,the clinical efficacy and safety of two groups were evaluated.RESULTS:After treatment,the ABCD2 score and NIHSS score were lower,the ADL score was higher in the observation group than those in the control group,with statistically significant differences(P＜0.05).After treatment,the CRP,Hcy,S100A1 protein and IL-6 levels were significantly lower,the SOD level was significantly higher in the observation group than those in the control group,with statistically significant differences(P＜0.05).The total effective rate[94.00％(47/50)vs.84.00％(42/50)]and incidence of adverse event[12.00％(6/50)vs.10.00％(5/50)]of the observation group were higher than those of the control group,the differences were not statistically significant(P＞0.05).CONCLUSIONS:Butylphthalide treatment based on conventional cerebrovascular disease regimen can effectively reduce the risk of stroke in patients with non-disabling ischemic cerebrovascular disease,relief neurological function damage,contribute to the reduction of inflammation and oxidative stress levels,which has certain clinical application value.
万方数据
维普
